Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) General Counsel Benjamin Looker sold 6,347 shares of Esperion Therapeutics stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $7.00, for a total value of $44,429.00. Following the sale, the general counsel now directly owns 64,453 shares of the company's stock, valued at approximately $451,171. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Esperion Therapeutics Stock Performance
NASDAQ:ESPR opened at $6.83 on Friday. The stock has a market capitalization of $503.26 million, a PE ratio of -1.50 and a beta of 0.23. Esperion Therapeutics, Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $8.87. The company has a fifty day moving average of $6.56 and a two-hundred day moving average of $6.98.
Get Esperion Therapeutics alerts:Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.12. The company had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. Research analysts forecast that Esperion Therapeutics, Inc. will post -3.65 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have commented on ESPR. StockNews.com upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, November 3rd. Morgan Stanley lifted their price objective on Esperion Therapeutics from $7.00 to $9.00 and gave the company an "underweight" rating in a research note on Wednesday, November 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $11.20.Institutional Trading of Esperion Therapeutics
Institutional investors have recently made changes to their positions in the company. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the 1st quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after purchasing an additional 1,761,117 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Esperion Therapeutics by 19.4% in the first quarter. Vanguard Group Inc. now owns 4,491,530 shares of the biopharmaceutical company's stock worth $20,841,000 after buying an additional 730,091 shares in the last quarter. Millennium Management LLC boosted its position in Esperion Therapeutics by 116.8% during the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock worth $17,212,000 after acquiring an additional 1,457,952 shares during the last quarter. Ikarian Capital LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter valued at about $13,067,000. Finally, State Street Corp raised its holdings in Esperion Therapeutics by 23.2% in the 3rd quarter. State Street Corp now owns 1,533,148 shares of the biopharmaceutical company's stock valued at $10,272,000 after acquiring an additional 288,609 shares during the last quarter. 85.87% of the stock is owned by institutional investors and hedge funds.
Esperion Therapeutics Company Profile
(Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
See Also
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.